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Abstract
Background: Langerhans cell histiocytosis (LCH), previously known as Histiocytosis X, is an infrequent disease
that congregates a wide spectrum of clinical presentations with variable systemic involvement. Unification of these
diseases under only one category is based on the almost identical histopathologic features of the lesions, but the
etiology and proper approach for each presentation remains controversial. The localized alternative of Langerhans
cell histiocytosis (LLCH), known as Eosinophilic Granuloma (EG) of bone, is the predominant clinical presentation of LCH.
The maxilla is involved in 1 % of the head and neck region cases, representing an uncommon condition in this area.
Case Presentation: In this clinical case report, it is described a case of a 16-year-old male patient with an asymptomatic
osteolytic lesion at first upper left molar apical level, a finding detected on control radiographic images was reported
as “Monostotic Eosinophilic granuloma of the maxillary bone”, which was later confirmed through an incisional biopsy.
A surgical excision was initially planned, but finally it was not performed due to a spontaneous healing of the lesion after
the incisional biopsy.
Conclusions: The presented case supports a conservative approach in the management of solitary EG of maxillary and
mandibular bone lesions and even supports an expectant attitude in the course of treatment given the possibility of a
spontaneous regression after the biopsy, especially in small lesions.
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Background
Lichtenstein and Jaffe introduced the term Histiocytosis
X in 1953 to encompass a group of uncommon granu-
lomatous proliferative disorders characterized by the
presence of histiocytic cells [1, 2]. The Eosinophilic granu-
loma is traditionally considered as one of the three clinical
manifestations of Histiocytosis X, which also includes
Hand-Schuller-Christian and Letterer-Siwe diseases [3].
Later in 1985 the generic name of this diseases was
changed to Langerhans Cell Histiocytosis (LCH), in recog-
nition to the principal component of the proliferative cell
population [2]. As LCH is an uncommon disease, only a
limited number of large surveys or randomized clinical
trials are available in scientific literature and many treat-
ment details remain either obscure or controversial [4, 5].
Only 1 % of the head and neck region cases of EG
involves the maxillary bone [1]. For this reason, the purpose
of this case report is to describe a rare case of Eosinophilic
Granuloma in a 16-year-old patient, which healed spontan-
eously after incisional biopsy, and to present a brief review
of the available literature on the topic.
Case presentation
A 16-year-old male patient, without any relevant aspects
in his medical history except a Non-Hodgkin lymphoma
of his father, which is currently being treated, and a
breast cancer of his mother, also in treatment. The pa-
tient was derived from the Hematology Unit for evalu-
ation and definitive treatment of an osteolytic lesion in
the left maxillary region with an evolution of nearly
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2 months. Thirty days before, the patient had consulted
at a dental service for a routine dental exam in which a
radiolucent image appeared in the radiographic study.
The patient underwent a biopsy of an asymptomatic
osteolytic lesion located at apical level of the first upper
left molar.
In his admission to our service, the oral and maxillo-
facial clinical examination did not show facial asymmetry,
swelling or solution of continuity in the left maxillary al-
veolar ridge. The patient only had a slight and generalized
gingival inflammation, and no other findings.
He brought images of a recent dental study (pano-
ramic radiography) and a report of a biopsy performed
30 days before. The imaging study reported an osteolytic
lesion in the left maxillary ridge, extending between the
first and second upper left molars, with projection to the
maxillary sinus [Fig. 1]. The biopsy report concluded
that the sample was consistent with bone monostotic
Eosinophilic granuloma (Langerhans histiocytosis). The
histophatological findings of the performed biopsy,
compatible with Eosinophilic granuloma, are showed in
the Fig. 2 and Fig. 3.
To complete the case study, additionally to the routine
preoperative laboratory tests (blood count, biochemical
profile and coagulation tests), a cone-beam CT (CBCT)
was requested, and to rule out compromise of other
bones, a scintigraphy was requested. Previously performed
paraffin embedded samples of biopsy were also requested.
Laboratory tests were normal. The new CBCT [Fig. 4]
showed inflammatory changes in relation to the left
maxillary sinus with great opacification, an area of oste-
olysis in connection with the roots of the upper left first
molar, causing soil discontinuity of the ipsilateral sinus;
and extensive loss of continuity of the oral bone plate,
compatible with post-surgical biopsy changes. Bone
scintigraphy showed an increase in osteoblast activity in
the left maxillary bone, related with the known bone
injury. There were no other findings of pathological sig-
nificance in the rest of the study [Fig. 5].
Given these images of sinus compromise, nasal
congestion and subsequent discharge reported by the
patient, it was decided to complete the study with
computed tomography (CT) of the sinuses before the
complete surgical removal of the lesion [Fig. 6], and refer the
patient to the assessment and care of an otolaryngologist.
The patient came back to us 3 months after his first
examination to schedule his surgical procedure, which
prompted new imaging study to redefine treatment
[Fig. 7].
Later studies showed recovery of the left maxillary sinus
transparency in spite of the persistence of mucosal thick-
ening of the sinus floor. Newly formed bone in the periph-
ery and between the roots was compromised by the initial
injury, and a decrease of the hypodense areas found in the
previous examination was also observed [Fig. 8].
Fig. 1 Panoramic radiograph obtained before biopsy, showing an osteolytic lesion in relation to periapex of the first upper left molar and
projecting toward the floor of the maxillary sinus (white arrows)
Fig. 2 Histological analysis shows fibrous connective tissue with
lymphoplasmacytic inflammatory infiltrate and strong presence of
eosinophils (Hematoxylin-Eosin. 40×)
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These findings were consistent with spontaneous
remission of the osteolytic lesion after the biopsy. The
patient underwent regular checks to ensure no recur-
rence of his original injury; the last check was 9 months
after the initial biopsy. Figures 9 and 10 show the grade
of bone repair in the originally affected area. Since the
EG is a benign lesion, which developed a spontaneous
remission in this case, our patient’s prognosis is excel-
lent, as long he follows his regular checks in order to
detect any early recurrence or new outbreaks for at
least 5 years.
Discussion
Langerhans cell histiocytosis is a group of disorders
characterized for a clonal proliferation of Langerhans
cells [2, 6], with a wide spectrum of clinical presenta-
tions, including solitary bone lesions with excellent
prognosis, known as eosinophilic granuloma, and other
Fig. 4 The CBCT showed veiling of the left maxillary sinus, soil discontinuity of ipsilateral sinus, related with the osteolytic lesion around the roots
of the upper left first molar; and extensive loss of continuity of the buccal bone plate, compatible with post-surgical biopsy changes
Fig. 3 Histiocyte-like cells with clear cytoplasm and pale rounded or
some indented nuclei can be observed. Prominent eosinophilic
granules and also some neutrophils are present
(Hematoxylin-Eosin. 100×)
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systemic presentations with a multi-organic, dissemi-
nated and progressive course, previously known as
Hand-Schüller-Christian syndrome and Letterer-Siwe
disease [3]. The current classification differentiates
between single system disease with one organ or system
involved and multisystem disease with two or more
systems involved that may include ‘risk organs’
(hematopoietic system, spleen and/or liver) [5].
This grouping of different entities has been based on
the similarities of the histopathologic appearance of the
histiocytic and eosinophilic proliferation and by the
involvement of Langerhans cells precursors [7]. A
presumptive diagnosis is made when the typical mor-
phological features of Langerhans cells are found, and it
is confirmed if it stains for S-100 protein, CD1a and/or
CD207 (Langerin) antigens are positive [4]. The detec-
tion of cytoplasmic inclusion bodies known as Birbeck-
Breatnach granules is another typical characteristic of
LCH [8]. When the diagnosis is made, bone scan and
PET are indicated to evaluate multiple involvements and
to discard the possibility of polyostotic disease [9].
The cause and pathogenesis of these disorders remains
unknown. It has been proposed that a basic immune
defect may lead to proliferation of Langerhans cells; or
Fig. 5 Bone scintigraphy showed an increase in osteoblast activity in the left maxillary bone, related with the known bone injury. No other
findings of pathological significance in the rest of the study
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that the Langerhans cell itself may carry a genetic defect
leading to abnormal cellular proliferation [8]. A key fea-
ture of this neoplasm is its clonal derivation from a sin-
gle cell, which does not necessarily mean malignancy
[6]. On the other hand, it is reported that proinflamma-
tory cytokines and chemokines as well as oncogenic B-
type Raf kinase (BRAF) gene mutations are involved in
the pathogenesis of EG [10]. BRAF mutations are
present in several malignant neoplasias including papil-
lary thyrd carcinoma [11]. Its finding in EG suggests a
neoplastic condition of the lesion, concept that must be
reevaluated considering the existence of spontaneous
resolution of this disorder. Differentiation disorders of
Langerhans cells have also been studied [12]. Recently, it
has been proposed a model of pathogenesis of Langer-
hans cell Histiocytosis in which there is an initial inflam-
matory condition potentiated by Interleukin 1, continued
by mutations of BRAF genes. Both processes are also
being considered as potential therapeutic targets [13].
Also, HCL has been associated with other malignan-
cies such as leukemias, lymphomas and other solid
tumors. This may precede, occur concurrently or follow
the diagnosis of LCH and should be considered at every
clinical visit [1, 4]. Acute lymphoblastic leukemia and
lymphoma occur more often prior to the diagnosis of
LCH, but they may be diagnosed up to 5 years after
LCH [4].
In our case, the patient also has a family history of
malignancies, although there is no clear family associ-
ation for the development of these disorders, we must
consider this precedence and assure clinical evaluations
over time.
Clinical course and prognosis of the disease depend on
the age of initial manifestation as well as the location
and the organs involved [8]. The anatomic site itself
(particularly in bone involvement), the volume of
involved soft tissue and local destruction degree have a
greater impact on the outcome of the disease than the
actual number of bones involved [5]. Multisystem dis-
ease (MS-LCH) generally has a worse prognosis and a
more complex treatment. Fortunately, EG is the pre-
dominant clinical form of LCH and accounts for 50 to
60 % of all cases of LCH [14]. Any organ or system of
the human body can be affected, but those more
Fig. 7 CBCT images of three months after first examination, showing recovery of the left maxillary sinus transparency although the mucosal
thickening of the floor persists
Fig. 6 CT images of sinus commitment, after the biopsy and before complete surgical removal of the lesion
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frequently involved are the skeleton (80 % of cases) and
the skin (33 %) [4].
EG of bone is a disease with an incidence of one new
case per 350,000 to 2 million per year [7, 8]. It is most
common in teenagers and adults, with approximately
75 % of all patients younger than 20 years old [1, 8, 14]
and 90 % under 40, with an average age of 19 [1]. Males
are affected twice as often as women [1]. In the head
and neck bone region, the compromised sites are skull
(27 – 43 %), mandible (7 – 9 %), maxillary bone (1 %)
and cervical vertebra (2 %), accordingly to the reported
by Hicks J. et al., 2005 [1]. Lesions are unifocal in 50 –
75 % of the cases, being 3 times more common than
multifocal involvement [1]. Our case report presents an
interesting clinical case of a unifocal lesion of alveolar
ridge of the maxillary bone, given its low incidence but
especially for its spontaneous regression. Although lit-
erature reports spontaneous remission of EG in several
locations including mandible, femur, intracranial bones,
lungs and orbit bones [15–17]; no reference to a specific
quantification of incidence was found. Several articles
recommend considering the “wait and see” policy when
this lesion is confirmed, but a closer and longer follow
up appears to be strictly necessary.
The clinical spectrum of EG in maxillary and man-
dibular bones is quite varied and may mimic a variety of
Fig. 8 Remarkable is the presence of new bone newly formed in the periphery and between the roots compromised by the initial injury and the
decrease in density areas found in previous pictures
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Fig. 9 CT images show the grade of bone repair in the originally affected area, nine months after biopsy
Fig. 10 Nine months after the biopsy was performed, it is possible to see the repaired bone in the area initially affected
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conditions, such as apical cysts, odontogenic tumors
(e.g., ameloblastoma), non-odontogenic tumors (e.g.,
central giant cell granuloma), inflammatory diseases (e.g.,
osteomyelitis), vascular malformations, and malignancies
[7, 14].
When there are clinical manifestations, the most
common signs and symptoms in the oral cavity are
intraoral mass, pain, gingival inflammation, bleeding,
mobile teeth, oral mucosal ulcer, impaired healing, and
halitosis [1, 7], and it is usually misdiagnosed as mar-
ginal periodontal infections [8]. On the other hand,
lesion may occasionally remain asymptomatic, leading to
underdiagnosis [9]. In our case the patient only referred
localized swelling associated with gingival inflammation,
with neither pain nor tooth mobility, and the lesion was
detected with a routine panoramic radiography.
Due to incomplete understanding of the pathogenesis
of LCH, treatment has been based on different empirical
strategies, considering the extent of the disease and the
severity at onset [4, 6]. There is also an agreement on
the fact that single system disease has good prognosis
with a high rate of spontaneous remission and negligible
mortality [18]. With unifocal bone disease, complete ex-
cision of bone lesions (curettage) may be indicated if the
lesion is small (<2 cm) and for lesions with a diameter of
2 to 5 cm, a biopsy and curettage is an option [4, 19]. In
the present case, surgical excision was proposed initially,
but apparently simple curettage during the diagnostic
biopsy turned out in remission at the control with CT
scan. Consequently, it was decided to keep an expectant
attitude, maintaining controls until the lesion’s total
remission. This option is the most conservative and less
invasive, and it is consistent with other cases presented
previously, which support a conservative approach
concerning treatment [2, 20, 21].
Another approach to solitary lesions treatment is an
intra lesional injection of steroids [22–24], however, the
standard treatment for LCH is not yet clear and surgery
is still the treatment of choice in these cases [8, 14].
Other therapeutic combinations of LCH include surgery,
chemotherapy and radiation, either individually or
together, which may be necessary in multisystem disease.
New therapeutic strategies are represented by monoclo-
nal CD-1a-antibody-therapy and gene transfer into
hemopoietic progenitor cells [8] and gene therapy [6].
Excision with or without radiation therapy has led to
more than 95 % disease-free survival. However, relapse
occurs in about 10 % of cases. Surgery alone has a 12 %
recurrence rate, compared with 25 % for radiation ther-
apy alone and 19 % for both combined therapies [1].
Patients without a histologically confirmed diagnosis
need to be carefully monitored by appropriate imaging
for at least 6 months after diagnosis in order to reassess
the need for biopsy and its justification, in order to
exclude a malignancy [4]. In the present case, the patient
has more than 1 year of postoperative controls. Besides,
bone scintigraphy fortunately discards the possibility of
polyostotic disease, which allowed us to maintain an
expectant approach of the lesion’s regression, without
the need of new surgery.
All patients should be followed for a sufficient time
period, defined as (i) at least 5 years after the end of
therapy; or (ii) 5 years after the last disease reactivation,
in those who did not receive systemic therapy; or (iii)
until final growth and pubertal development have oc-
curred [4, 25]. In our case, since the pubertal growth of
the patient is probably finished, a minimum of 5 years
follow-up is necessary, to exclude recurrence.
Conclusions
Clinicians who treat maxillofacial disorders should be
aware of the possibilities of LCH diagnosis and subsequent
spectrum of clinical presentations. Faced with a diagnosis
of HCL is mandatory to carry out a thorough examination
and discard their participation in other systems.
The main lesson of this case report is the usefulness
and validity of the use of conservative approaches in the
management of EG solitary maxillary bone lesions and
that it even supports an expectant attitude toward the
possibility of spontaneous regression only performing
biopsy, especially in small lesions.
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